Defibrotide

- TRADE NAME: Defitelio (Jazz)
- INDICATIONS: Hepatic veno-occlusive disease in patients with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
- CLASS: Oligonucleotide
- HALF-LIFE: <2 hours
Contra-indicated for concomitant administration with systemic anticoagulant or fibrinolytic therapy.
Please login to see the rest of this drug profile
SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
LOCAL
OTHER
Page last updated 09/19/2018